期刊文献+

乙型脑炎病毒E蛋白抗原表位E39特异性单克隆抗体的制备 被引量:6

Preparation of monoclonal antibody specific to envelope protein epitope E39 of Japanese encephalitis virus
在线阅读 下载PDF
导出
摘要 为了制备乙型脑炎病毒E蛋白抗原表位特异性单克隆抗体,将编码乙型脑炎病毒E蛋白抗原表位E39的DNA序列进行人工合成,随后插入表达载体pGEX-6p-1的限制性酶切位点BamHⅠ与XhoⅠ之间,构建了表位肽与GST的融合表达质粒。该表位融合蛋白经亲和层析纯化后免疫BALB/c小鼠,按常规方法进行细胞融合。以化学合成的E39表位多肽为抗原,对融合细胞上清进行间接ELISA筛选。结果,筛选出1株分泌E39表位特异性抗体的杂交瘤细胞株,该杂交瘤细胞分泌抗体能力稳定。经鉴定,该单克隆抗体亚型为IgG2b,轻链类型为κ链。结果表明,用表位融合蛋白为抗原可以制备表位特异性单克隆抗体。 The DNA sequence encoding envelope protein epitope E39 of Japanese encephalitis virus was synthesized and inserted into prokaryotic expression vector pGEX-6p-1 between sites BarnH Ⅰ and Xho Ⅰ . BALB/c mice were immunized with the purified epitope fusion protein GST-E39 expressed in Escherichia coli BL21. The myeloma cells SP2/0 were fused with splenocyte of the immunized BALB/c mice. Hybridoma cell lines were screened and selected by an indirect ELISA using the synthesized peptide E39 as antigen. One hybridoma cell line 5G7 was identified and selected for stably secreting epitope E39-specific antibody. The monoclonal antibody was identified to be IgG2b subtype,and its light chain was κ chain. The results confirmed that the epitope-specific monoclonal antibody could be successfully prepared with the epitope fusion protein as antigen.
出处 《中国兽医科学》 CAS CSCD 北大核心 2008年第2期133-136,共4页 Chinese Veterinary Science
基金 国家自然科学基金项目(30700027) 中国农业科学院哈尔滨兽医研究所所长基金项目(2006,2007) 黑龙江省博士后基金项目(LBH-Z05213)
关键词 乙型脑炎病毒 E蛋白 单克隆抗体 表位 Japanese encephalitis virus envelope protein monoclonal antibody , epitope
  • 相关文献

参考文献10

  • 1VAUGHN D W, HOKE C H Jr. The epidemiology of Japanese encephalitis:prospeets for prevention [J]. Epldemiol Rev, 1992,14(1):197-221.
  • 2VAN DEN HURK A F, MONTGOMERY B L,NORTHILL J A,et al. Short report:the first isolation of Japanese encephalitis virus from mosquitoes collected from mainland Australia [J]. Am J Trop Med Hyg ,2006,75(1) :21-25.
  • 3PARIDA M,DASH P K,TRIPATHI N K,et al. Japanese encephalitis outbreak, India, 2005[J]. Emerg Infect Dis, 2006,12 (9) : 1427-1430.
  • 4HOMBACH J ,BARRETT A D,CARDOSA M J ,et al. Review on flavivirus vaccine development. Proceedings of a meeting jointly organized by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand[J]. Vaccine, 2005,23 (21 ) : 2689-2695.
  • 5KOLASKAR A S,KULKARNI-KALE U. Prediction of threedimensional structure and mapping of conformational epitopes of envelope glycoprotein of Japanese encephalitis virus [J]. Virology,1999,261(1):31-42.
  • 6SEIF S A, MORITA K, MATSUO S, et al. Finer mapping of neutralizing epitopes on the C-terminal of Japanese encephalitis virus E-protein expressed in recombinant Escherichia coli system[J]. Vaccine, 1995,13(16) : 1515-1521.
  • 7LIN C W, WU S C. A functional epitope determinant on domain Ⅲ of the Japanese encephalitis virus envelope protein interacted with neutralizing-antibody combining sites [J]. J Virol,2003,77(4) :2600-2606.
  • 8KOHLER G,MILSTEIN C. Continuous cultures of fused cells secreting antibody of predefined specificity [J]. Nature, 1975, 256(5517) :495-497.
  • 9OEM J K, KYE S J, LEE K N,et al. Development of synthetic peptide ELISA based on nonstructural protein 2C of foot and mouth disease virus[J]. J Vet Sci ,2005,6(4):317-325.
  • 10周艳君,华荣虹,王云峰,安同庆,刘金霞,杨金雨,华玉卓,童光志.SARS-CoV单克隆抗体的制备及抗原表位的初步鉴定[J].生物工程学报,2005,21(2):211-215. 被引量:7

二级参考文献17

  • 1de Haan CA, Volders H, Koetzner CA et al. Coronaviruses maintain viability despite dramatic rearrangements of the strictly conserved genome organization. J Virol, 2002, 76 (24): 12491-12502
  • 2Ruan YJ, Wei CL, Vega VB et al. Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet, 2003,361 (9371): 1779 - 1795
  • 3Morkett APA, Cavanagh D, Brown TDK. Monoclonal antibodies directed against viron proteins. J Gen Virol, 1984, 65:2281 - 2286
  • 4Enjuanes L, Sola I, Almazan F et al. Coronavirus derived expression systems. Adv Exp Med Biol, 2001, 494:309 - 321
  • 5Narayanan K, Maeda A, Maeda J et al, Characterization of the coronavirus M protein and nucleocapsid interaction in infected cell.J Virol, 2000, 74(17) :8127 - 8134
  • 6Krueger DK, Kelly SM, Lewicki DN et al. Variations in disparate regions of the murine coronavirus spike protein impact the initiation of membrane fusion. J Virol 2001, 75(6) :2792 - 2802
  • 7Gallagher TM, Buchmeier MJ. Coronavirus spike protein in viral entry and pathogenesis. Virology, 2001, 20:279 (2) :371 - 374
  • 8Taguchi F, Shimazaki YK. Functional analysis of an epitope in the S2 subunit of the murine coronavirus spike protein: involvement in fusion activity. J Gen Virol, 2000, 81 (12) :2867 - 2871
  • 9Zhang GS(章谷生), Rong BP(容秉培), Eds. Application of Monoclonal Antibody in Medicine. Shanghai Science and Technology Publishing House( 上海科学技术出版社 ), 1987, pp. 299 - 300
  • 10Sacchi S, Federico M, Dastoli G et al. Treatment of B-cell nonHodgkin' s lymphoma with anti CD 20 monoclonal antibody Rituximab. Crit Rev Oncol Hematol, 2001, 37 (1): 13 - 25

共引文献6

同被引文献90

引证文献6

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部